Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial.

Ann Rheum Dis · 2013 · PMC3711370 · PMID 22915624

Europe PMC DOI

hedged sentence

0.0780

closest p · 1.6× alpha

0.0780

boldest claim

The sentences

approached significancep=0.078so close (0.05 < p ≤ 0.1)

Difference between treatment groups in adjusted mean synovitis score change approached significance (−0.69 (95% CI −1.45 to 0.08); p=0.078).

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.